NCT05485077 A Prospective Cohort Study on Colorectal Cancer Screening in Community Population
| NCT ID | NCT05485077 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Singlera Genomics Inc. |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 18,000 participants |
| Start Date | 2022-07-09 |
| Primary Completion | 2028-07-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 18,000 participants in total. It began in 2022-07-09 with a primary completion date of 2028-07-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will validate the real world results of polygene methylation detection in colorectal cancer in a large prospective community cohort. In this study, questionnaire survey and polygene methylation detection technology of colorectal cancer were used as preliminary screening methods, and colonoscopy was used as further validation examination method to screen colorectal cancer and precancerous lesions. The diagnosis and outcome of all lesions were based on colonoscopy and pathological examination.
Eligibility Criteria
Inclusion Criteria: 1. Chronological age ≥40 years; 2. Full capacity for action; 3. After enrollment, the participants were able to complete the Colorectal Cancer Risk Factor Assessment Questionnaire and the annual follow-up interviews; 4. In the course of the study, the information related to tumor diagnosis in other hospitals can be timely fed back to the researchers; Exclusion Criteria: 1. History of colorectal cancer and other malignant tumors; 2. Previous colorectal resection; 3. undergoing any cancer-related treatment; 4. Patients who have received major surgical treatment such as blood transfusion or transplantation within 3 months; 5. Participate in other interventional clinical investigators within 3 months; 6. Pregnant or lactating women; 7. Have autoimmune disease, hereditary disease, mental illness/disability, etc 8. Poor compliance, unable to complete the study.
Contact & Investigator
Rui Liu, Doctor
PRINCIPAL INVESTIGATOR
Singlera Genomics Inc.
Frequently Asked Questions
Who can join the NCT05485077 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05485077 currently recruiting?
Yes, NCT05485077 is actively recruiting participants. Contact the research team at yuanping_632@163.com for enrollment information.
Where is the NCT05485077 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05485077 clinical trial?
NCT05485077 is sponsored by Singlera Genomics Inc.. The principal investigator is Rui Liu, Doctor at Singlera Genomics Inc.. The trial plans to enroll 18,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.